A randomized, multicenter, phase 3 study of nivolumab vs sorafenib as first-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): CheckMate-459.

被引：28
|
作者：
Sangro, Bruno
Park, Joong-Won
Dela Cruz, Christine Marie
Anderson, Jeffrey
Lang, Lixin
Neely, Jaclyn
Shaw, James W.
Cheng, Ann-Lii
机构：
[1] Clin Univ Navarra & CIBERHD, Liver Unit, Pamplona, Spain
[2] Natl Canc Ctr, Ctr Liver Canc, Goyang, South Korea
[3] Bristol Myers Squibb, Princeton, NJ USA
[4] Natl Taiwan Univ, Coll Med, Grad Inst Oncol, Taipei, Taiwan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.TPS4147
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4147
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Cost-effectiveness of sorafenib as a first-line treatment for advanced hepatocellular carcinoma
    Zhang, Pengfei
    Yang, Yu
    Wen, Feng
    He, Xiaofeng
    Tang, Ruilei
    Du, Zedong
    Zhou, Jing
    Zhang, Jian
    Li, Qiu
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2015, 27 (07) : 853 - 859
  • [32] Nivolumab dose escalation and expansion in patients with advanced hepatocellular carcinoma (HCC): The CheckMate 040 study.
    Melero, Ignacio
    Sangro, Bruno
    Yau, Thomas Cheung
    Hsu, Chiun
    Kudo, Masatoshi
    Crocenzi, Todd S.
    Kim, Tae-You
    Choo, SuPin
    Trojan, Jorg
    Meyer, Tim
    Welling, Theodore Hobart
    Yeo, Winnie
    Chopra, Akhil
    Anderson, Jeffrey
    Dela Cruz, Christine Marie
    Lang, Lixin
    Neely, Jaclyn
    Tang, Hao
    El-Khoueiry, Anthony
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [33] Randomized, phase 3 study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma (HCC): RATIONALE-301 age ≥65 years subgroup
    Vogel, A.
    Kudo, M.
    Qin, S.
    Chen, Y.
    Li, S.
    Boisserie, F.
    Abdrashitov, R.
    Finn, R.
    Meyer, T.
    Zhu, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S167 - S168
  • [34] Efficacy and safety of nivolumab in asian patients with advanced hepatocellular carcinoma (HCC): Subanalysis of the CheckMate 040 Study
    Choo, S. P.
    Yau, T.
    Hsu, C.
    Kang, Y-K.
    Hou, M-M.
    Yeo, W.
    Numata, K.
    Chopra, A.
    Baakili, A.
    Dela Cruz, C.
    Zhao, H.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [35] Nivolumab plus cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial
    Choueiri, T. K.
    Powles, T.
    Burotto, M.
    Bourlon, M. T.
    Zurawski, B.
    Oyervides Juarez, V. M.
    Hsieh, J. J.
    Basso, U.
    Shah, A. Y.
    Suarez, C.
    Hamzaj, A.
    Barrios, C. H.
    Richardet, M.
    Pook, D.
    Tomita, Y.
    Escudier, B.
    Zhang, J.
    Simsek, B.
    Apolo, A. B.
    Motzer, R. J.
    ANNALS OF ONCOLOGY, 2020, 31 : S1159 - S1159
  • [36] Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
    Li, Yan
    Liang, Xueyan
    Li, Huijuan
    Yang, Tong
    Guo, Sitong
    Chen, Xiaoyu
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [37] Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
    Li, Yan
    Liang, Xueyan
    Li, Huijuan
    Yang, Tong
    Guo, Sitong
    Chen, Xiaoyu
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [38] A phase I study of bavituximab and sorafenib in patients with advanced hepatocellular carcinoma (HCC)
    Yopp, Adam
    Arriega, Yuii
    Singal, Amit
    Mansour, John
    Bach, Glen
    Thorpe, Phillip
    CANCER RESEARCH, 2012, 72
  • [39] Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: A Korean multicenter study
    Lee, Sangheun
    Kim, Beom Kyung
    Kim, Seung Up
    Park, Soo Young
    Kim, Ja Kyung
    Lee, Hyun Woong
    Park, Jun Yong
    Kim, Do Young
    Ahn, Sang Hoon
    Tak, Won Young
    Kweon, Young Oh
    Lee, Jung Il
    Lee, Kwan Sik
    Kim, Hyung Joon
    Han, Kwang-Hyub
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2014, 29 (07) : 1463 - 1469
  • [40] Phase Ib study of regorafenib (REG) plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC)
    El-Khoueiry, Anthony B.
    Kim, Richard D.
    Harris, William P.
    Sung, Max W.
    Waldschmidt, Dirk
    Iqbal, Syma
    Zhang, Xiaojing
    Nakajima, Keiko
    Galle, Peter R.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
12345